Initial Medication in Patients of Newly Diagnosed Parkinson’s Disease in Taiwan (original) (raw)

Abstract

Introduction: Several treatment guidelines for Parkinson's disease (PD) had been proposed in recent decades. The aim of current study was to investigate the initial medication utilized in newly diagnosed PD subjects in Taiwan during an elevenyear period. Methods: A total of 7,550 patients with newly diagnosed Parkinsonism were retrospectively enrolled from the National Health Insurance Research Database of Taiwan from 2000 to 2010. After excluding patients at risk of secondary or atypical Parkinsonism, those never receiving medication or having incomplete data, 1,645 subjects were included. The participants were then divided into four treating regimen groups, namely levodopa (LD) only group, dopamine agonist (DA) only group, LD+DA group, and No-LD, No-DA group. The demographic data and medication retention rate were compared across the four treatment groups. Results: LD only and No-LD, No-DA regimens were the main initial choice of PD treatment in Taiwan. LD containing drugs were more often prescribed to the elderly population than the other two treatment regimens, while No-LD, No-DA medication was the major initial choice for younger patients. DA only regimen occupied only 3-4% of the initial PD prescriptions and was given predominantly by neurologists. Over the eleven-year period, there is a trend for the middleaged population to receive medication containing LD as initial treatment. The one year retention rate of anti-Parkinsonism medication was around 30-50% in our population. Age, polypharmacy, change of one-year daily levodopa equivalent dosage and newly onset of dementia, stroke and psychiatric diseases all affect drug compliance in PD patients. Conclusions: This is the first long-term study to explore initial pharmacotherapies in an Asian PD population. We hope to provide evidence for adjusting government policies and public education of physicians and PD patients in the future.

Loading...

Loading Preview

Sorry, preview is currently unavailable. You can download the paper by clicking the button above.

References (30)

  1. Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55: 181-184.
  2. Van Den Eeden SK, Tanner CM, Bernstein AL, Fross RD, Leimpeter A, et al. (2003) Incidence of Parkinson's disease: variation by age, gender, and race/ ethnicity. Am J Epidemiol 157: 1015-1022.
  3. Mayeux R, Marder K, Cote LJ, Denaro J, Hemenegildo N, et al. (1995) The frequency of idiopathic Parkinson's disease by age, ethnic group, and sex in northern Manhattan, 1988-1993. Am J Epidemiol 142: 820-827.
  4. Jain L, Benko R, Safranek S (2012) Clinical inquiry. Which drugs work best for early Parkinson's disease? J Fam Pract 61: 106-108.
  5. Jankovic J, Poewe W (2012) Therapies in Parkinson's disease. Curr Opin Neurol 25: 433-447.
  6. Fox SH, Katzenschlager R, Lim SY, Ravina B, Seppi K, et al. (2011) The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease. Mov Disord 26 Suppl 3: S2-41.
  7. Ahlskog JE, Muenter MD (2001) Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 16: 448-458.
  8. Kostic V, Przedborski S, Flaster E, Sternic N (1991) Early development of levodopa-induced dyskinesias and response fluctuations in young-onset Parkin- son's disease. Neurology 41: 202-205.
  9. Quinn N, Critchley P, Marsden CD (1987) Young onset Parkinson's disease. Mov Disord 2: 73-91.
  10. Whone AL, Watts RL, Stoessl AJ, Davis M, Reske S, et al. (2003) Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL- PET study. Ann Neurol 54: 93-101.
  11. Holloway RG, Shoulson I, Fahn S, Kieburtz K, Lang A, et al. (2004) Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 61: 1044-1053.
  12. Poewe W, Antonini A, Zijlmans JC, Burkhard PR, Vingerhoets F (2010) Levodopa in the treatment of Parkinson's disease: an old drug still going strong. Clin Interv Aging 5: 229-238.
  13. Fernandez HH (2012) Updates in the medical management of Parkinson disease. Cleve Clin J Med 79: 28-35.
  14. Kondo T (2002) Initial therapy for Parkinson's disease: levodopa vs. dopamine receptor agonists. J Neurol 249 Suppl 2: II25-29.
  15. Koller WC (2002) Treatment of early Parkinson's disease. Neurology 58: S79- 86.
  16. Silver DE, Ruggieri S (1998) Initiating therapy for Parkinson's disease. Neurology 50: S18-22; discussion S44-18.
  17. Vlaar A, Hovestadt A, van Laar T, Bloem BR (2011) The treatment of early Parkinson's disease: levodopa rehabilitated. Pract Neurol 11: 145-152.
  18. Lyons KE, Pahwa R (2011) Diagnosis and initiation of treatment in Parkinson's disease. Int J Neurosci 121 Suppl 2: 27-36.
  19. Morrish P (2012) Prescribing in Parkinson's disease: a story of hope and adverse events. Pract Neurol 12: 335-340.
  20. Swarztrauber K, Koudelka C, Brodsky MA (2006) Initial pharmacotherapy in a population of veterans with Parkinson disease. Neurology 66: 1425-1426.
  21. Huse DM, Castelli-Haley J, Orsini LS, Lenhart G, Abdalla JA (2006) Patterns of initial pharmacotherapy for Parkinson's disease in the United States. J Geriatr Psychiatry Neurol 19: 91-97.
  22. Hsieh LP, Huang CY (2011) Trends in the use of antiepileptic drugs in Taiwan from 2003 to 2007: a population-based national health insurance study. Epilepsy Res 96: 81-88.
  23. Lin YC, Yang CC, Chen YJ, Peng WC, Li CY, et al. (2012) Utilization of statins and aspirin among patients with diabetes and hyperlipidemia: Taiwan, 1998- 2006. J Chin Med Assoc 75: 567-572.
  24. Lopez-Sendon JL, Mena MA, de Yebenes JG (2012) Drug-induced parkinson- ism in the elderly: incidence, management and prevention. Drugs Aging 29: 105-118.
  25. Lachenmayer L (2003) Differential diagnosis of parkinsonian syndromes: dynamics of time courses are essential. J Neurol 250 Suppl 1: I11-14.
  26. Tarrants ML, Denarie MF, Castelli-Haley J, Millard J, Zhang D (2010) Drug therapies for Parkinson's disease: A database analysis of patient compliance and persistence. Am J Geriatr Pharmacother 8: 374-383.
  27. Parkinson Study G (2000) Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group. JAMA 284: 1931-1938.
  28. Kulkarni AS, Balkrishnan R, Anderson RT, Edin HM, Kirsch J, et al. (2008) Medication adherence and associated outcomes in medicare health maintenance organization-enrolled older adults with Parkinson's disease. Mov Disord 23: 359-365.
  29. Ng WT, Caslake R, Counsell CE (2007) Non-completion of changes to prescribed medications in people with Parkinson's disease. Age Ageing 36: 333- 336.
  30. Grosset KA, Bone I, Grosset DG (2005) Suboptimal medication adherence in Parkinson's disease. Mov Disord 20: 1502-1507.